soul trial oral semaglutide cardiovascular outcomes results 2025 (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Abstract 4351008: Comparing Cardiovascular Outcomes

As a result, you may be hungrier while breastfeeding

Surprising Fact The weight loss drug Wegovy could lower the risk of adverse cardiovascular events by 20%, according to data from a trial shared by Novo Nordisk in August

DF is not an essential nutrient, but it plays an important part in enhancing digestive capacity and maintaining intestinal health

Tirzepatide may contribute to low blood pressure in some situations, especially if blood pressure is already being treated with medication or if a person becomes dehydrated

1, 3 6 Although most frequently the chest, shoulder or upper arm are involved, examples have occurred everywhere on the skin surface

Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus